Class / Patent application number | Description | Number of patent applications / Date published |
514349000 | Nitrogen attached directly to the six-membered hetero ring by nonionic bonding | 25 |
20090124668 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes modulators of MCP-1 of formula (I): | 05-14-2009 |
20090215834 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF - Disclosed are compounds of the Formula V | 08-27-2009 |
20090221649 | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage - The invention relates to substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines of formula (I) and their use in medicaments for the prophylaxis and/or treatment of reperfusion injury and damage. | 09-03-2009 |
20090291987 | NOVEL POLYMORPH OF (5-AMINO-6-METHOXY-3-PYRIDINCARBONYL) CARBAMIC ACID 2-(S)-HYDROXYMUTILIN 14-ESTER - The present invention relates to a novel polymorph, to processes for the preparation of the polymorph and to the use of the polymorph in medicine, particularly antibacterial therapy. | 11-26-2009 |
20100120869 | COMPOUNDS AND METHODS FOR PKC THETA INHIBITION - The present invention provides a method of selectively inhibiting PKCθ in the presence of PKCδ, by administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I. The present invention also provides a method of inhibiting cytokine synthesis in a T cell, a method of inhibiting T cell proliferation, and a method of inhibiting the replication of and cytokine production by T lymphocytes, while not stimulating or inhibiting the replication of B lymphocytes. | 05-13-2010 |
20110034520 | Inhibitors of P38 Map Kinase - Compounds of formula (I) are p38 MAP kinase inhibitors useful for the treatment of autoimmune and inflammatory diseases: wherein: G is —N═ or —CH═; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5-13 ring members; R6 is hydrogen or optionally substituted CrC3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula (IA); wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members; z is O or 1; —X | 02-10-2011 |
20110071197 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS - There is provided compounds of formula I, wherein ring A, D | 03-24-2011 |
20110112152 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS - This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases. | 05-12-2011 |
20110218219 | SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES - The present invention relates to substituted sulphonamido phenoxybenzamide compounds of general formula (I): | 09-08-2011 |
20120214850 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES - The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines. | 08-23-2012 |
20120252849 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: | 10-04-2012 |
20120322834 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: | 12-20-2012 |
20130040997 | NOVEL PYRIDINE CARBOXYLIC ACID BASED COMPOUND USED AS A P2X1 AND P2X3 RECEPTOR ANTAGONIST, A PRODUCTION METHOD FOR THE SAME AND A COMPOSITION COMPRISING THE SAME - Provided are a novel pyridine carboxylic acid based compound used as a P2X | 02-14-2013 |
20130072527 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS. | 03-21-2013 |
20130245074 | NOVEL COMPOUND AND MEDICAL USE THEREOF - Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa. | 09-19-2013 |
20130267565 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER - The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R | 10-10-2013 |
20140088159 | ENZYME AND RECEPTOR MODULATION - Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the α,α-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells. | 03-27-2014 |
20140206727 | AMIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS INSECTICIDE - A compound represented by Formula (1): | 07-24-2014 |
20140329867 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS - The present invention relates to use of inhibitors of Notch signalling pathway selected from the group consisting of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, in treating and/or preventing cancers. | 11-06-2014 |
20140336227 | 3-AMINO LACTAMS AS ANTI-INFLAMMATORY AGENTS - Compounds, pharmaceutical compositions of general formula (I) or (I′) or a pharmaceutically acceptable salt thereof, and methods for treating an inflammatory disorder: | 11-13-2014 |
20140371277 | COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder. | 12-18-2014 |
20160068488 | PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF - The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): | 03-10-2016 |
20160096805 | KINASE INHIBITOR - There is provided a compound of formula I, | 04-07-2016 |
20160101090 | INHIBITION OF TRK KINASE MEDIATED TUMOR GROWTH AND DISEASE PROGRESSION - It has been shown that Compound 1 unexpectedly and potently inhibits TRK kinases, including all three forms of TRK: NTRK1, NTRK2, and NTRK3. Additionally it has been shown that Compound 1 potently inhibits oncogenic mutated forms of TRK kinases, including fusion proteins. By way of exemplification, Compound 1 potently inhibits the NTRK1 oncogenic fusion protein TPM3/NTRK1 in cellular assays. Compound 1 inhibits TRK kinase mediated tumor growth in vivo in a TPM3/NTRK1 xenograft model. | 04-14-2016 |
20160151509 | ENZYME AND RECEPTOR MODULATION | 06-02-2016 |